GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Altman Z-Score
中文

argenx SE (argenx SE) Altman Z-Score : 30.30 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 30.8 is strong.

argenx SE has a Altman Z-Score of 30.30, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for argenx SE's Altman Z-Score or its related term are showing as below:

ARGX' s Altman Z-Score Range Over the Past 10 Years
Min: 3.87   Med: 22.1   Max: 46.02
Current: 30.8

During the past 13 years, argenx SE's highest Altman Z-Score was 46.02. The lowest was 3.87. And the median was 22.10.


argenx SE Altman Z-Score Historical Data

The historical data trend for argenx SE's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Altman Z-Score Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.90 14.00 34.91 37.62 30.19

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.62 37.19 38.19 52.62 30.19

Competitive Comparison of argenx SE's Altman Z-Score

For the Biotechnology subindustry, argenx SE's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where argenx SE's Altman Z-Score falls into.



argenx SE Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

argenx SE's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.8147+1.4*-0.5294+3.3*-0.0668+0.6*50.0199+1.0*0.27
=30.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $4,542 Mil.
Total Current Assets was $4,124 Mil.
Total Current Liabilities was $423 Mil.
Retained Earnings was $-2,405 Mil.
Pre-Tax Income was -61.178 + -83.279 + -83.861 + -76.178 = $-304 Mil.
Interest Expense was -0.278 + -0.231 + -0.207 + -0.188 = $-1 Mil.
Revenue was 406.837 + 329.789 + 270.55 + 219.14 = $1,226 Mil.
Market Cap (Today) was $22,256 Mil.
Total Liabilities was $445 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(4123.737 - 422.993)/4542.458
=0.8147

X2=Retained Earnings/Total Assets
=-2404.844/4542.458
=-0.5294

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-304.496 - -0.904)/4542.458
=-0.0668

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=22256.401/444.951
=50.0199

X5=Revenue/Total Assets
=1226.316/4542.458
=0.27

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

argenx SE has a Altman Z-Score of 30.30 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


argenx SE  (NAS:ARGX) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


argenx SE Altman Z-Score Related Terms

Thank you for viewing the detailed overview of argenx SE's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE (argenx SE) Business Description

Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.